See the Aventi 340B Rebate Model Demo.
340B TPA FAQ

How does a 340B TPA prevent diversion?

A 340B TPA helps prevent diversion by checking every claim against your eligibility rules before it counts as 340B. Each prescription has to trace back to a registered, eligible site, an eligible prescriber, a visit documented in your health record and a patient who was an outpatient at the time. Only claims that pass every check build up 340B replenishment, reversed claims are taken back out, and self-audits test samples to catch what the filters missed. The legal duty to prevent diversion stays with the covered entity; the TPA runs the controls you define and keeps the records that prove them.[1][3][5]

What counts as diversion
“A covered entity shall not resell or otherwise transfer the drug to a person who is not a patient of the entity.”

42 U.S.C. § 256b(a)(5)(B). Manufacturers and HRSA can audit the records that show compliance.[1]

How it shows up in HRSA audits

HRSA posts the findings from finalized covered entity audits. The diversion findings for fiscal year 2025 audits are mostly described in a few recurring phrases:[7]

  • “340B drugs dispensed at contract pharmacies for prescriptions written at ineligible sites”
  • “340B drugs dispensed at covered entity for prescriptions written at ineligible sites”
  • “340B drug dispensed to inpatient”

Each of these is a claim that should have failed a check: the wrong site, or the wrong patient status. That is where a TPA’s controls do their work. For the audit process itself, see how to prepare for a HRSA 340B audit.

The starting point

The patient test every claim has to pass

HRSA’s 1996 patient definition guidelines still guide its audits. Under them, an individual is a patient of a covered entity only if all of the following are true:[2][8]

  1. 1
    You have a relationship with the individual

    The covered entity has established a relationship with the person and maintains records of their health care.

  2. 2
    Your professional is responsible for the care

    The person receives care from a health care professional employed by the covered entity, or under a contract or other arrangement (such as a referral for consultation) where responsibility for the care stays with the covered entity.

  3. 3
    The service fits your grant or designation

    For grantees and FQHC look-alikes, the service is consistent with the scope for which the grant or designation was given. Disproportionate share hospitals are exempt from this part.

And one exclusion

Someone isn’t a patient if the only service they got from the covered entity was having a drug dispensed for use at home.[2]

A 2023 federal court decision in Genesis Health Care v. Becerra rejected a narrower HRSA reading of “patient,” but relief was limited to Genesis, and HRSA says the decision applies solely to Genesis Health Care.[8][9]

Prevent

Seven checks a claim clears before it counts as 340B

HRSA’s contract pharmacy guidance calls for a tracking system suitable to prevent diversion and a system to verify patient eligibility. In practice, a TPA runs each dispense through a series of checks built from your data: sites, providers, encounters and patient status. A claim that fails any one of them stays non-340B.[3]

Check 1
Site check
Did the prescription come from an eligible location?

The originating clinic must be the parent site or a registered child site. For hospitals, the clinic has to appear as reimbursable on the most recently filed Medicare cost report, and off-site clinics must be registered in 340B OPAIS.[6][10]

Stops
Prescriptions from unregistered or non-reimbursable clinics
Check 2
Prescriber check
Is the prescriber on your eligible provider list?

Prescribers are matched to the providers you employ or contract with. Referral prescriptions qualify only when you keep a documented referral and the consult summary showing your responsibility for the care.[2][10][11]

Stops
Outside prescribers with no referral record
Check 3
Encounter match
Is the drug tied to a visit in your health record?

The claim is matched to an encounter documented in the covered entity’s record, using the encounter rules your written policies set. A dispense with no supporting visit doesn’t qualify; dispensing alone doesn’t make someone your patient.[2][10][11]

Stops
Fills for people whose only service was the dispense
Check 4
Outpatient status
Was the patient an outpatient at the time?

340B is an outpatient program. Your policies define inpatient vs. outpatient (including observation and discharge prescriptions), and the TPA applies that definition to each use. Inpatient use is excluded.[4][6][10]

Stops
Doses given to admitted inpatients
Check 5
Pharmacy check
Was it filled at a pharmacy you’re set up with?

Contract pharmacy claims count only from pharmacy locations covered by a written agreement and registered on your 340B OPAIS record.[3][11]

Stops
Fills at unregistered pharmacy locations
Check 6
Replenishment match
Does each 340B order trace back to qualified use?

Only qualified dispenses accumulate, by exact 11-digit NDC, with billing units per package set correctly. Purchases, dispenses and inventory should reconcile, and any variance gets resolved and documented.[10]

Stops
Orders placed ahead of eligible use, or unit errors that inflate balances
Check 7
Reversal handling
When a claim is reversed, does its accumulation come back out?

Reversed claims and eligibility data corrections have to be removed from the balance. If 340B stock was already ordered against them, the result is an ineligible purchase to fix.[13]

Stops
Reversed claims left in the balance, which leads to negative accumulations

Checks 6 and 7 are where inventory mechanics come in. For more detail, see what virtual inventory is in 340B and how accumulators and split billing work. Medicaid claims face a separate filter for duplicate discounts.

Where the risk sits

Three places diversion tends to slip in

Contract pharmacies

Contract pharmacies also fill prescriptions for the general public, which GAO noted increases the risk of 340B drugs going to ineligible patients. HRSA’s posted audit findings repeatedly cite contract pharmacy fills for prescriptions written at ineligible sites.[7][14]

Different eligibility logic

OIG found that covered entities, pharmacies and TPAs used different methods to identify eligible prescriptions, so similar prescriptions were treated differently from one entity to another. Your rules need to be written down and applied the same way everywhere.[15]

Mixed-use hospital areas

Where inpatients and outpatients are treated in the same department, HRSA says the hospital must have tracking systems that keep 340B drugs from being used for inpatients, and shouldn’t use 340B there if it can’t.[6]

Setting up pharmacies correctly is part of the fix. See how contract pharmacy setup works with a 340B TPA.

Detect

Self-audits that test whether the checks are working

Filters only catch what they’re configured for. HRSA recommends quarterly internal audits and annual independent audits of contract pharmacies, with written procedures for reviewing the eligibility system and reconciling dispensing, purchasing and billing records. The 2010 guidance gives examples: quarterly sample comparisons of eligible prescriptions to dispensing records, and a six-month comparison of 340B purchasing and dispensing records.[3][5]

Hospital diversion self-audit

Sample from purchases, then trace

  1. 1.Pick 20 invoices from 340B purchases: the 10 with the most lines and the 10 with the highest total cost
  2. 2.Choose 20 different drugs from those invoices, then one 340B dispense or administration of each
  3. 3.Check each one for eligible location, registered site, outpatient status, eligible provider and a documented visit
  4. 4.Reconcile units purchased, dispensed and on hand (or in the accumulator) for each drug
  5. 5.Pull one day of accumulations across the 340B, GPO and WAC accounts and confirm exact NDC matching

From the Prime Vendor Program’s quarterly self-audit for hospitals subject to the GPO prohibition.[10]

Contract pharmacy self-audit

Sample from fills, then trace

  1. 1.Take a random sample from each pharmacy arrangement, larger for big chains (for example 30) than for a small independent (for example 10)
  2. 2.Add targeted picks: drugs likely to be miscalculated, high-cost specialty drugs and anything billed to Medicaid
  3. 3.Confirm each fill came from a registered pharmacy location under a signed agreement
  4. 4.Trace each prescription to an eligible service, an eligible prescriber and a documented encounter
  5. 5.For referral prescriptions, confirm your record shows responsibility for the care

From the Prime Vendor Program’s contract pharmacy self-audit, recommended at least quarterly.[11]

A good TPA makes this fast: every claim keeps the site, prescriber, encounter and accumulation history an auditor will trace. See what reporting a 340B TPA should provide.

Correct

When a claim shouldn’t have qualified

01

Fix the cause

Correct the rule, provider list, site mapping or unit setup that let the claim through, so the error stops recurring.[10]

02

Find the full extent

Look back for every claim the same error touched, not just the sampled ones. HRSA requires entities with audit findings to assess the full extent of noncompliance.[14]

03

Make manufacturers whole

Return or credit and rebill with the wholesaler while windows are open (typically 3–6 months from purchase for credit and rebill), otherwise repay the manufacturer directly. HRSA expects repayment even when an issue isn’t material.[13]

04

Decide on materiality

Compare the result to the material breach threshold in your policies. Adverse events include 340B drugs going to ineligible patients and 340B drugs missing from inventory.[12]

05

Self-disclose if needed

If diversion occurred or you can’t otherwise meet your compliance duties, HRSA says to submit a self-disclosure to 340bselfdisclosure@hrsa.gov while you correct the issue.[5][12]

Why repeat errors matter. If HRSA finds diversion in two or more audits, it may treat it as systematic and egregious, as well as knowing and intentional. Under the statute that can mean removal from the 340B program and a bar on re-entry for a period of time.[1][4]

The TPA runs the controls

What stays your call

HRSA’s guidance says the covered entity has, and continues to bear, full responsibility for preventing diversion, even when a contract pharmacy and a TPA are involved. Your TPA applies your decisions to every claim, so the decisions need to be written down.[3]

For a full breakdown of duties, see who is responsible for 340B compliance.

  • How your entity applies the patient definition, written in policies and procedures
  • Where the line between inpatient and outpatient sits, including observation and discharge
  • Which prescribers, referral arrangements and sites count, and keeping that list current
  • Your material breach threshold and the decision to self-disclose
  • Annual recertification, signed by your authorizing official
How Aventi helps

Eligibility checks you can stand behind

Precise eligibility matching

We configure eligibility matching to your sites, providers and policies, with referral capture beyond your walls, and run claim capture in real time across a 10,000+ pharmacy network.

Audit-ready claims

Every claim stays audit-ready, with duplicate discount monitoring, Good Faith Inquiry tracking and negative balance management, plus a dedicated account manager when you run a self-audit or face a HRSA audit.

Split billing that stays tied

Purchases are separated by patient eligibility across 340B, GPO and WAC accounts with no end-of-month true-ups. We support 300 covered entities, 24 of them hospitals.

Ready for 2027 rebates

The rebate module is Included for Aventi TPA clients, with real-time 340B ESP and Truzo (Kalderos) integration. Learn about the 2027 340B rebate model.

FAQ

340B diversion prevention: common questions

Diversion is giving a 340B drug to someone who isn’t a patient of the covered entity. The statute says a covered entity shall not resell or otherwise transfer a 340B drug to a person who is not its patient. In HRSA audits it often shows up as 340B drugs dispensed for prescriptions written at ineligible sites, or 340B drugs given to inpatients.[1][7]

The covered entity, applying HRSA’s 1996 patient definition guidelines, which HRSA says continue to guide its audits. The TPA applies the rules you set to each claim. The patient test looks at your relationship and records, who is responsible for the care, and, for grantees, whether the service fits the grant scope.[2][8]

No. A TPA filters claims and keeps the records, but the covered entity keeps full responsibility for preventing diversion. HRSA recommends quarterly internal audits and annual independent audits of contract pharmacies to test that the system works.[3][5]

They can be, when the person is your patient and responsibility for the care stays with you, for example a referral for consultation. Self-audit tools ask for a documented referral and a summary of the referral visit in your record. Without that documentation, a claim from an outside prescriber shouldn’t qualify.[2][10][11]

Only if they meet the patient definition on their own. HRSA says 340B has never been a general employee pharmacy benefit, and an employer or insurer relationship alone isn’t enough to make someone eligible.[6]

Usually repayment to affected manufacturers, which the covered entity has to identify and contact, plus a corrective action plan. Diversion found in two or more audits may be treated as systematic and egregious, as well as knowing and intentional, which can lead to removal from the program.[1][4]

HRSA recommends quarterly internal audits and annual independent audits of contract pharmacies. The Prime Vendor Program’s self-audit tools are also built to run at least quarterly, sampling purchases, dispenses and accumulations.[5][10][11]

In 2023 a federal court in South Carolina held that HRSA’s narrower reading of “patient” in a letter to Genesis Health Care conflicted with the statute, but limited relief to Genesis. HRSA says the decision applies solely to Genesis Health Care, so other covered entities should keep following the current guidelines.[8][9]

Sources

  1. 42 U.S.C. § 256b(a)(5)(B) (prohibiting resale or transfer), (a)(5)(C) (auditing) and (d)(2)(B)(v) (sanctions) (Cornell LII) — https://www.law.cornell.edu/uscode/text/42/256b
  2. Federal Register, Notice Regarding Section 602 of the Veterans Health Care Act of 1992, Patient and Entity Eligibility, 61 FR 55156 (Oct. 24, 1996), Definition of a Patient — https://www.govinfo.gov/content/pkg/FR-1996-10-24/html/96-27344.htm
  3. Federal Register, Notice Regarding 340B Drug Pricing Program—Contract Pharmacy Services, 75 FR 10272 (Mar. 5, 2010), essential elements (g) and (h) and appendix — https://www.federalregister.gov/documents/2010/03/05/2010-4755/notice-regarding-340b-drug-pricing-program-contract-pharmacy-services
  4. HRSA Office of Pharmacy Affairs, Program Integrity (audit procedures, repayment, repeat findings) — https://www.hrsa.gov/opa/program-integrity
  5. HRSA FAQ, What are the audit and compliance parameters under the contract pharmacy guidelines? — https://www.hrsa.gov/about/faqs/what-are-audit-compliance-parameters-under-contract-pharmacy-guidelines
  6. HRSA 340B FAQs (child site registration, four-walls clinics, discharge prescriptions, mixed-use settings, employees) — https://www.hrsa.gov/opa/faqs
  7. HRSA, Program Integrity: FY25 Audit Results (updated Oct. 30, 2026) — https://www.hrsa.gov/opa/program-integrity/fy-25-audit-results
  8. HRSA, 340B Patient Definition Compliance Resources — https://www.hrsa.gov/opa/educational-resources/patient-definition-resources
  9. Genesis Health Care, Inc. v. Becerra, No. 4:19-cv-01531-RBH (D.S.C. Nov. 3, 2023), order on summary judgment — https://storage.courtlistener.com/recap/gov.uscourts.scd.250571/gov.uscourts.scd.250571.143.0.pdf
  10. 340B Prime Vendor Program (Apexus), Self-Audit: Prevention of Diversion and GPO Violation (DSH/PED/CAN) — https://www.340bpvp.com/Documents/Public/340B%20Tools/gpo-prohibition-hospitals-self-audit-prevention-of-diversion-and-gpo-violation.docx
  11. 340B Prime Vendor Program (Apexus), Self-Audit: Contract Pharmacy — https://www.340bpvp.com/Documents/Public/340B%20Tools/self-audit-contract-pharmacy.docx
  12. 340B Prime Vendor Program (Apexus), Establishing Material Breach Threshold — https://www.340bpvp.com/Documents/Public/340B%20Tools/establishing-material-breach-threshold.docx
  13. Apexus, Expert Tip: Resolve Negative 340B Accumulations (340B Report, Nov. 30, 2023) — https://www.apexus.com/about-us/articles-and-updates/expert-tip-resolve-negative-340b-accumulations
  14. GAO-18-480, Drug Discount Program: Federal Oversight of Compliance at 340B Contract Pharmacies Needs Improvement (June 2018) — https://www.gao.gov/products/gao-18-480
  15. HHS Office of Inspector General, Contract Pharmacy Arrangements in the 340B Program, OEI-05-13-00431 (Feb. 2014) — https://oig.hhs.gov/reports/all/2014/contract-pharmacy-arrangements-in-the-340b-program/

Last updated November 20, 2026. This page is general information, not legal advice. Check HRSA’s current guidance and your own counsel for your program.